Johnson Booster 85% Effective Against Omicron: South Africa Study

The New Diplomat
Writer

Ad

Peter Obi Condemns “Derogatory” Labels, Says His Supporters Are Not Street Urchins

By Abiola Olawale Peter Obi, presidential candidate of the Labour Party in the 2023 election, has condemned the use of derogatory labels against his supporters, stressing that no Nigerian should ever be described as a “street urchin.” In a statement posted on his official X handle, the former Anambra State governor decried what he called…

Atiku blasts Tinubu govt over Nnaji scandal, says resignation ‘whitewash of forgery’

By Obinna Uballa Former Vice President Atiku Abubakar has condemned the resignation of Uche Nnaji, erstwhile Minister of Innovation, Science and Technology, describing it as “an attempt to whitewash yet another scandal” under President Bola Tinubu’s administration. Nnaji resigned on Tuesday after an investigation by Premium Times alleged that he submitted forged academic and NYSC…

“My Resignation Not An Admission of Guilt,” Nnaji Declares

By Abiola Olawale Uche Nnaji, Nigeria's erstwhile Minister of Innovation, Science, and Technology, has vehemently denied any wrongdoing, insisting his recent resignation from President Bola Tinubu's cabinet was a "principled decision" rather than a concession to guilt. The controversy, which has dominated headlines for over a week, centered on claims that Nnaji allegedly submitted falsified…

Ad

AFP — A booster of US coronavirus vaccine Johnson & Johnson was 85 percent effective in preventing serious illness in areas where Omicron was dominant, a South African trial study indicated Thursday.

The South African Medical Research Council conducted the study on health workers from November 15 to December 20, but it has still not been peer-reviewed.

It found the top-up jab to largely protect staff in a country where the highly transmissible strain is now behind most Covid cases.

“Data from the… study confirm that the Johnson & Johnson COVID-19 booster shot provides 85 percent effectiveness against hospitalization in areas where Omicron is dominant,” Johnson & Johnson said.

“This adds to our growing body of evidence which shows that the effectiveness of the Johnson & Johnson Covid-19 vaccine remains strong and stable over time, including against circulating variants such as Omicron and Delta,” it said.

Around half a million South African health staff have received Johnson jabs as part of clinical trials.

Africa’s hardest-hit country, South Africa has recorded more than 3.4 million cases and 90,000 deaths since the start of the pandemic.

An earlier South African study in December found the Pfizer/BioNTech vaccine to be less effective overall against Omicron, but still prevented hospital admissions by up to 70 percent.

Ad

Unlocking Opportunities in the Gulf of Guinea during UNGA80
X whatsapp